What Are the Different Ranitidine Interactions?
Ranitidine, also known as furanilamine, is a potent histamine H2 receptor antagonist. The effect is 5-8 times stronger than cimetidine, and the duration is longer. It can effectively inhibit the secretion of gastric acid caused by the stimulation of histamine, pentagastrin and carbamylcholine, reduce the activity of gastric acid and gastric enzymes, and is mainly used for the treatment of hyperacidity and heartburn.
- Drug Name
- Ranitidine
- Alias
- Furfurylamine, metroniduridine
- Foreign name
- Ranitidine
- Whether prescription drugs
- Non-prescription drugs
- Dosage form
- tablet
- Athletes use with caution
- Inadvertent use
- Whether to include health insurance
- Incorporate
- CA registration number
- [66357-35-5]
- Molecular formula
- C13H22N4O3S
- Molecular weight
- 314.40
- Pharmacopoeia
- JP14
- Ranitidine, also known as furanilamine, is a potent histamine H2 receptor antagonist. The effect is 5-8 times stronger than cimetidine, and the duration is longer. It can effectively inhibit the secretion of gastric acid caused by the stimulation of histamine, pentagastrin and carbamylcholine, reduce the activity of gastric acid and gastric enzymes, and is mainly used for the treatment of hyperacidity and heartburn.
Ranitidine compounds
Ranitidine information
- Chinese name:
- Chinese alias: ranitidine hydrochloride; furanodamine hydrochloride; furanodamine hydrochloride; metroniduridine; stomach antaidine; good stomach; stomach antai; Ovidad; furanide; radixide; sis Tower
- English name: ranitidine
- English alias: Taural; Sostril; Terposen; Trigger; U1tidine; Zantac; AH-19065
- CAS number: 66357-35-5
- Molecular formula: C 13 H 22 N 4 O 3 S
- Molecular weight: 314.40400
- Exact mass: 314.14100
- PSA: 111.56000
- LogP: 2.76400
Ranitidine physical and chemical properties
- Appearance and properties: white powder
- Density: 1.184 g / cm 3
- Melting point: 69-70 ° C
- Boiling point: 437.1ºC at 760 mmHg
- Refractive index: 1.558
- Water solubility: 24.7 mg / mL
Ranitidine Safety Information
- Customs Code: 2932999099
- WGK Germany: 2
- Safety instructions: S22-S24 / 25
- RTECS number: KM6557000 [1]
The history of ranitidine
- Ranitidine, like cimetidine, is currently the most widely used drug for treating ulcers. Developed by Glaxo. Synthesized by Price, etc. in 1976, Bradshaw elucidated its pharmacology in 1979, Berstad reported in 1980 that it was effective for duodenal ulcers, and was marketed in 1981. Applications in hundreds of countries. China was produced by Shanghai No. 6 Pharmaceutical Factory in 1985 [2] .
Ranitidine Pharmacopoeia Standard
Ranitidine source (name), content (potency)
- This product is N'-methyl-N- [2-[[[[[[[[Dimethylamino) methyl] -2-furanyl] methyl] thio] ethyl] -2-nitro-1 , 1-ethylenediamine hydrochloride. Calculated on dry basis, C 13 H 22 N 4 O 3 S · HCl should be 97.5% 102.0%.
Ranitidine traits
- This product is off-white to light yellow crystalline powder; it has an offensive odor; it has a slightly bitter and astringent taste; it is prone to deliquescent and its color becomes darker after absorbing moisture.
- This product is soluble in water or methanol, slightly soluble in ethanol, and almost insoluble in acetone.
Ranitidine identification
- (1) Take about 0.2g of this product, put it in a test tube, and slowly heat it with a small fire. The generated gas can make the wet lead acetate test paper appear black.
- (2) In the spectrum recorded under the content determination item, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the reference solution.
- (3) Take this product, add water to make a solution containing 10 g per 1 ml, and measure according to ultraviolet-visible spectrophotometry (Appendix IVA of Pharmacopoeia Part II of the 2010 edition). It has maximum absorption at 228nm and 314nm wavelengths.
- (4) The infrared light absorption spectrum of this product should be consistent with the control spectrum (Figure 401 of "Infrared Spectra of Drugs").
- (5) Identification of chlorides in the aqueous solution of this product (Appendix III of Part Two of the 2010 Pharmacopoeia).
- You can choose (2), (4), and (5) or (1), (2), (3), and (5).
Ranitidine check
- Clarity and color of the solution
- Take 1.0g of this product and dissolve it in water to make it 100ml. The solution should be clear and colorless; if color is developed, it should not be deeper than the yellow colorimetric standard solution 3 (Appendix A of Part Two of the 2010 Pharmacopoeia).
- acidity
- Take 0.20g of this product, add 10ml of water to dissolve it, and measure it according to law (Appendix VIH of Part Two of the Pharmacopoeia, 2010 Edition). The pH value should be 4.5 6.5.
- relative substance
- Take this product, add water to dissolve and dilute it to make a solution containing about 1mg per 1ml as the test solution; take 1ml precisely, place it in a 100ml volumetric flask, dilute to the mark with water, and shake as the control solution. According to the chromatographic conditions under the content determination item, take 10ul of the control solution and inject it into the liquid chromatograph, and adjust the detection sensitivity so that the peak height of the main component chromatographic peak is about 20% of the full scale. Then accurately measure 10ul each of the control solution and the test solution, inject them into the liquid chromatograph, and record the chromatogram. If there are impurity peaks in the chromatogram of the test solution, the area of the impurity peak with a relative retention time of about 1.75 shall not be greater than 0.5 times (0.5%) the area of the main peak of the control solution, and the area of the other single impurity peaks shall not be greater than 0.2 times the area of the main peak of the control solution. (0.2%), the sum of the peak areas of other impurities should not be greater than 0.5 times (0.5%) the area of the main peak of the control solution. Any peak less than 0.05 times the area of the main peak of the control solution in the chromatogram of the test solution can be ignored.
- Loss on drying
- Take this product, use phosphorus pentoxide as a desiccant, and dry under reduced pressure at 60 ° C for 4 hours, and the weight loss should not exceed 0.75% (Appendix L of the second part of the Pharmacopoeia of the 2010 edition).
- Residue on ignition
- Take 1.0g of this product and check it according to law (Appendix N of Part Two of the 2010 Pharmacopoeia). The residual residue shall not exceed 0.1%.
- Heavy metal
- Take the residue left under the burning residue and check it according to law (Appendix H of the 2010 edition of the Pharmacopoeia, the second method), the content of heavy metals must not exceed 20 parts per million [3] .
Determination of ranitidine
- It was determined by high performance liquid chromatography (Appendix VD of Part Two of the Pharmacopoeia, 2010 Edition).
- Chromatographic conditions and system suitability tests
- Use octadecylsilane bonded silica as a filler (recommended column: Kromasil Cl8, 150mm × 4.6mm, 5um or equivalent column); mobile phase A is phosphate buffer (take 6.8ml phosphoric acid and put it in 1900ml) In water, add 8.6ml of 50% sodium hydroxide solution, add water to 2000ml, adjust the pH to 7.1 ± 0.05 with phosphoric acid or 50% sodium hydroxide solution) -acetonitrile (98: 2), and mobile phase B is phosphate buffer solution- Acetonitrile (78:22); gradient elution according to the following table; detection wavelength is 230nm; flow rate is 1.5ml per minute; column temperature is 35 ° C. Take about 0.1g of ranitidine hydrochloride, put it in a 100ml measuring bottle, add 1ml of 50% sodium hydroxide solution, add about 60ml of water, shake to dissolve, dilute with water to the mark, shake well, and leave it at room temperature for 1 hour. 10ul was injected into the liquid chromatograph, and the chromatogram was recorded. Adjust the flow rate or flow comparison example, so that the retention time of the main component chromatographic peak is about 12 minutes, the retention time of the impurity I peak relative to the ranitidine peak is about 0.85, and the theoretical number of plates based on the ranitidine peak is not less than 5000 The resolution of the Ranitidine peak and the impurity I peak should be greater than 4.0.
| Time (minutes) | Mobile phase A (%) | Mobile phase B (%) |
| 0 | 100 | 0 |
| 15 | 0 | 100 |
| twenty three | 0 | 100 |
| twenty four | 100 | 0 |
| 30 | 100 | 0 |
- Assay
- Take about 22mg of this product, accurately weigh it, place it in a 200ml measuring bottle, add water to dissolve and dilute to the mark, shake well, and accurately measure 10ul into the liquid chromatograph and record the chromatogram; also take about ranitidine hydrochloride reference substance 22mg, determined by the same method. Calculate the peak area according to the external standard method, and get [3] .
Ranitidine Categories
- H2 receptor blockers.
Ranitidine storage
- Shaded, sealed and stored in a cool, dark and dry place.
Ranitidine
- (1) Ranitidine hydrochloride tablets (2) Ranitidine hydrochloride injection (3) Ranitidine hydrochloride capsules [3]
Ranitidine medication description
Ranitidine classification
- Digestive System Drugs> Acid and Gastric Mucosal Protection
Ranitidine traits
- Its hydrochloride is commonly used as off-white or light yellow crystalline powder; it has an offensive odor, has a slightly bitter and astringent taste, is prone to deliquescent, and becomes darker after absorbing moisture. Soluble in water or methanol, slightly soluble in ethanol, and almost insoluble in acetone. Melting point 137-143 ° C.
Ranitidine dosage form
- 1. Tablets: 150mg, 300mg each;
- 2. Capsule: 150mg;
- 3. Injection: 50mg (2ml), 50mg (5ml), 150mg (2ml), 300mg (2ml).
Ranitidine pharmacological effects
- Ranitidine's active ingredient is Ranitidine. Ranitidine is a selective H2 receptor antagonist that competitively blocks histamine and gastric parietal cells.
- Ranitidine structure
Ranitidine pharmacokinetics
- Ranitidine is rapidly but incompletely absorbed orally, and has first-pass metabolism, so its bioavailability is only 50%, and its absorption is not affected by food and antacids. After a single oral ranitidine 150mg, the blood concentration reached a peak in 1 to 3 hours, the average peak concentration was 400ng / ml, the effective blood concentration was 100ng / ml, and the effect could be maintained for 8 to 12 hours. Within 12 hours after oral administration, the gastric acid secretion caused by pentagastrin can be reduced by 30%. Intravenous ranitidine 1mg / kg, the instantaneous blood concentration is 3 000ng / ml, maintained above 100ng / ml for 4h; the blood concentration reached a peak within 30 ~ 60min after intravenous drip at 0.5mg / kg per hour, There was a positive correlation between peak concentration and dose. Ranitidine is widely distributed in the body, with an apparent volume of distribution of 1.9 L / kg and a plasma protein binding rate of approximately 15%. Animal experiments show that ranitidine is higher in the digestive organs, liver and kidneys, and lower in ovaries and eyeballs. It can reach the fetus through the placenta. The concentration in the milk is higher than the blood concentration, and the concentration in the cerebrospinal fluid is about 1/30 to 1/20 of the blood concentration. Ranitidine has a half-life of about 2 to 3 hours, which is slightly longer than that of cimetidine; in renal insufficiency, the half-life is prolonged. Most are excreted in the form of the kidney, with a renal clearance of 7.2 ml / kg per minute. A small amount is metabolized in the liver to N-oxides, S-oxides, and desmethylranitidine, which are also excreted in the urine. Bile is excreted with feces. After intravenous injection, 93% of the dose is excreted in the urine, 5% is excreted in the stool; 60% to 70% of the oral dose is excreted in the urine, and 25% is excreted in the stool. Within 24 hours, 35% of the oral dose and 70% of the intravenous dose are excreted from the urine in their original form [4] .
Ranitidine dosage
- 1. Oral: (1) duodenal ulcer and benign gastric ulcer: acute phase treatment: the standard dose is 150mg each time, twice a day, taken at breakfast and dinner; or 300mg once before bedtime. The course of treatment is 4-8 weeks, and can be treated for 12 weeks if necessary. Most patients were cured within 4 weeks, and a few were cured within 8 weeks. It is reported that taking 300mg once a night is better than 150mg twice a day. Patients with duodenal ulcer, 300 mg twice daily treatment plan, the cure rate for 4 weeks of medication is higher than 150 mg each time, 300 mg twice daily or at night, and the increase in dosage does not cause adverse reactions The rate is increased; Long-term treatment: usually use night clothes at 150mg per day. Patients with acute duodenal ulcer healing should undergo maintenance treatment for more than 1 year to avoid recurrence of the ulcer.
- (2) Gastric mucosal damage caused by non-steroidal anti-inflammatory drugs: Treatment in the acute phase: 150 mg each time, 300 mg twice daily or overnight, the course of treatment is 8 to 12 weeks; Prevention: in non-steroidal anti-inflammatory drugs At the same time as the inflammation medicine treatment, take 150mg each time, twice daily or 300mg at night.
- (3) Ulcer: 150mg each time, 2 times a day, the vast majority of patients are cured within 4 weeks, and those who have not completely cured usually cure within the next 4 weeks;
- (4) Gastric-esophageal reflux disease: acute reflux esophagitis: 150 mg each time, 300 mg twice daily or at night for 8 to 12 weeks; moderate to severe esophagitis: the dose can be increased to every 150 mg twice daily for 12 weeks; Long-term treatment of reflux esophagitis: 150 mg orally twice daily.
- (5) Zhuo-Ai syndrome: a large amount should be used, 600 ~ 1200mg per day.
- (6) Intermittent onset dyspepsia: The standard dose is 150 mg each time, twice a day for 6 weeks of treatment.
- (7) To prevent repeated bleeding caused by stress ulcer bleeding or peptic ulcer in severely ill patients; once the patient can resume eating, 150 mg orally twice daily can be used instead of injection.
- (8) Prevention of Mendelson's syndrome: 150 mg 2 hours before anesthesia and 150 mg the night before anesthesia. Injections are also available. Obstetric delivery patients can take 150mg orally every 6 hours. If general anesthesia is required, non-granular antacids (such as sodium citrate) should be given.
- 2. Intramuscular injection: for the treatment of ulcer bleeding, 25-50mg each time, once every 4-8 hours.
- 3. Intravenous injection: (1) Peptic ulcer bleeding: 25 to 50 mg each time, once every 4 to 8 hours. 50mg of ranitidine injection was diluted to 20ml with normal saline or 5% glucose for slow intravenous injection (more than 2min). (2) Preoperative medication: 100 mg intravenously 1.5 h before surgery.
- 4. Intravenous infusion: (1) Peptic ulcer bleeding: intermittent intravenous infusion at a rate of 25 mg per hour for 2 hours, twice a day or once every 6 to 8 hours. (2) Preoperative medication: Intravenous infusion of 100-300mg, 100ml of 5% glucose injection was added, and the drip was completed in 30min [4] .
Ranitidine precautions
- (1) Patients with suspected cancerous ulcers should be diagnosed before use to avoid delay in treatment.
- (2) Banned for pregnant women and lactating women. Children under 8 years are disabled.
- (3) After intravenous injection, some patients experienced facial sensation of heat, dizziness, nausea, sweating, and stomach irritation, which disappeared for 10 minutes. Itching and redness sometimes occur at the site of intravenous injection and disappear after 1 hour. Sometimes it can also cause anxiety, excitement, forgetfulness, etc.
- (4) It is toxic to the liver, but can be recovered after stopping the drug. Use with caution in patients with liver and kidney dysfunction.
- (5) Feminization of male breasts is rare, and the incidence increases with age.
- (6) It can reduce the absorption of vitamin B12, and long-term use can cause deficiency of B12 [5] .
Ranitidine is contraindicated
- Patients with liver dysfunction and elderly patients occasionally experience mental disorders such as disorientation, lethargy, and anxiety after taking the drug.
- Patients with liver and kidney dysfunction should be used with caution. Pregnant women, nursing women and children under 8 years are prohibited.
- This product is mainly excreted by the kidney. When severe renal insufficiency, the half-life is prolonged, and the blood concentration is increased. Care should be taken to adjust the dose. Pregnant women and children under 8 years are prohibited [6] .
Ranitidine drug interactions
- 1. When combined with phenytoin sodium, the blood concentration of the latter can be increased; after ranitidine is stopped, the phenytoin blood concentration can be rapidly decreased.
- 2. When combined with procainamide, the latter's clearance can be reduced.
- 3. When combined with bismuth preparations, it is superior to ranitidine alone in the aspects of gastric ulcer healing, eradication of H. pylori, and reduction of ulcer recurrence.
- 4. When combined with antibiotics against Helicobacter pylori, it can reduce ulcer recurrence.
- 5. Studies have shown that ranitidine can increase the hypoglycemic effect of oral sulfonylurea hypoglycemic agents (such as glipizide and glibenclamide) in diabetic patients and cause serious hypoglycemia. However, ranitidine has also been reported to weaken the effect of glibenclamide. Therefore, when combined use should be alert to possible hypoglycemia or hyperglycemia. It is also recommended that diabetics should avoid the simultaneous use of ranitidine and sulfonylureas.
- 6. Compound antacids containing aluminum hydroxide and magnesium hydroxide can reduce the peak concentration of ranitidine in blood and reduce the area under the curve, but there is no change in the removal of ranitidine.
- 7. Because gastrointestinal topical administration can reduce the digestive tract absorption of ranitidine, it should be taken at intervals between the two, if necessary, more than 2h.
- 8. Ranitidine can reduce the absorption of vitamin B12.
- 9. Ranitidine can reduce the absorption of ampicillin in the intestine, inhibit its metabolism in the liver, and reduce its renal clearance. However, it is mainly to reduce the intestinal absorption, so the overall result is a decrease in the blood concentration of ampicillin.
- 10. It has been reported that ranitidine (intravenous injection) can reduce the absorption of enoxacin, but has no effect on the plasma concentration of ciprofloxacin.
- 11. Ranitidine is safer than cimetidine in combination with anticoagulants or antiepileptics.
- 12. In combination with warfarin, lidocaine, diazepam, propranolol (propranolol) and other drugs metabolized by the liver, the blood concentration of ranitidine will not increase and adverse reactions will occur. However, ranitidine can reduce liver blood flow, so when used in combination with drugs such as propranolol and lidocaine, which have a large effect on liver blood flow, the effects of these drugs can be delayed [4] .
Ranitidine indications
- For the treatment of active ulcers and diseases of high gastric acid secretion. Intravenous injection of this product can reduce gastric acid secretion by 90%, and can be used for acute gastric mucosal damage complicated by stress and acute gastric mucosal damage caused by aspirin. For Zollinger-Ellison syndrome, a large amount of ranitidine can suppress high gastric acid secretion and promote the relief of symptoms. It is also used to prevent gastric acid reflux with aspiration pneumonia after general anesthesia or major surgery and in debilitated coma patients.
- Applicable to gastric ulcer, duodenal ulcer, postoperative ulcer, reflux esophagitis, etc. [6] .
Ranitidine adverse reactions
- (1) Nausea, rash, constipation, fatigue, headache, dizziness, etc. are common.
- (2) Compared with cimetidine, it has less adverse effects on renal function, gonad function and central nervous system.
- (3) Occasionally bradycardia occurs after intravenous injection.
- (4) A small number of patients caused mild liver damage after taking the drug. The symptoms disappeared and the liver function returned to normal after stopping the drug. It was suspected to be an allergic reaction to the drug, regardless of the amount of the drug.
- (5) Long-term use can continuously reduce the acidity of gastric juice, which is beneficial to bacteria breeding in the stomach, thereby reducing nitrate in the food to nitrite and forming N-nitroso compounds.
- Dizziness, nausea, sweating, and gastrointestinal irritation or discomfort may occur after intravenous injection. Itching and redness sometimes occur at the site of intravenous injection, and disappear after 1 hour. Can cause anxiety, excitement, forgetfulness, etc. Can cause liver damage, interstitial nephritis, can be restored after stopping the drug. Feminization of male breasts is rare, but increases with age. Can reduce the absorption of vitamin B12, long-term use can cause B12 deficiency.
- After intravenous injection, some patients may experience nausea, sweating, and facial burning. Slight dizziness, constipation, drowsiness, and diarrhea were occasionally seen after oral administration, but generally did not affect continued treatment.
- Cardiovascular system: This product can cause sudden arrhythmia, bradycardia, cardiogenic shock, and mild atrioventricular block. In general, there is no warning. Although patients who are more sensitive to cholinergic neurons may have warning signs, for critically ill patients, taking ranitidine requires cardiac function monitoring or concurrently taking atropine for prevention.
- Nervous System: Headaches are more commonly reported and sometimes more severe. However, because this product can penetrate the blood-brain barrier, it causes reversible unconsciousness, mental abnormalities, abnormal movements, agitation, and insomnia.
- Hematopoietic system: Reduced granulocytes and decreased platelet counts are common adverse reactions. In patients with poor health, taking this product may trigger further deterioration of blood conditions.
- Digestive system: constipation, diarrhea, nausea, vomiting, abdominal pain, and occasional reports of pancreatitis.
- Others: rubella, bronchial asthma, fever, anaphylactic shock, transient aminotransferase elevation, renal impairment, etc. Symptoms can be improved or disappeared by reducing the dosage or stopping the drug [6] .
Ranitidine poisoning
- Ranitidine is a selective H2 receptor antagonist, which can effectively inhibit the secretion of gastric acid caused by histamine, pentagastrin and food stimulation, and reduce the activity of gastric acid and enzymes. Sex hormones have no effect. The effect is 5-8 times stronger than cimetidine. The drug is absorbed orally quickly and is not affected by food and antacids. Its half-life is slightly longer than that of cimetidine, about 2 to 2.7 hours. Most were excreted from the kidneys as prototypes, and the total amount of prototypes and metabolites recovered in 24 hours of urine was 45% of the total oral intake. The usual amount is 2 / d, 150mg / time. Pregnant and lactating women are prohibited, and children under 8 years are prohibited. Use with caution in patients with liver and kidney dysfunction.
- Clinical manifestation
- 1. Adverse reactions are as follows:
- (1) Dizziness, nausea, sweating, and stomach irritation may occur in some patients after intravenous injection, and disappear on their own for about 10 minutes. Itching and redness sometimes occur at the site of the intravenous injection. Sometimes it can also cause anxiety, excitement, forgetfulness, etc.
- (2) It is toxic to the liver, but can be recovered after stopping the drug.
- 2. Toxic reaction see the related content of cimetidine.
- diagnosis
- The main points of diagnosis of ranitidine poisoning are:
- With the history of ranitidine application, the above manifestations appear.
- treatment
- The main points of treatment of ranitidine poisoning are:
- See related content of cimetidine.
- 1. General adverse reactions can disappear by themselves after withdrawal.
- 2. Liver and kidney function damage should be actively taken to protect liver and kidney function.
- 3. For severe arrhythmia, anti-arrhythmic drugs can be applied according to the type of arrhythmia.
- 4. Symptoms of allergic reactions can be treated with antihistamines or glucocorticoids [7] .
New use of ranitidine
- Clinical findings have shown that ranitidine is also effective in treating recurrent oral ulcers and other diseases.
Ranitidine recurrent oral ulcer
- The use of ranitidine in the treatment of recurrent oral ulcers generally relieves pain within 1 to 2 days and heals within 3 to 5 days. The total effective rate is 100%, while the total effective rate of the control group treated with metronidazole is 85%, which is significant. The difference. Usage: Oral ranitidine, 150 mg / time, 2 times / day, or grind with ranitidine, and apply it directly to the ulcer surface, 3 times / day, until the symptoms disappear.
Ranitidine mumps
- Some people use ranitidine to treat patients with mumps. The effect is significant, and the effect is significantly better than the control group treated with morpholinam. Usage: Oral ranitidine, 15 mg / kg body weight · day, divided into 2 doses, continuously for 3 days. If the fever is too high, you can cooperate with physical cooling.
Ranitidine ulcerative colitis
- The total effective rate of ranitidine in patients with ulcerative colitis was 95%. Usage: Oral ranitidine, 150 mg / time, once a day, once a day, for 3 consecutive months.
Ranitidine wart gastritis
- Ranitidine was used to treat patients with verrucous gastritis, and the significant effect was obtained within one week. The total effective rate was 87%, while the total effective rate of the control group was only 33%. The difference between the two groups was very significant. Usage: Oral ranitidine, 150 mg / time, once in the morning and evening, delivered in warm water, 5 weeks as a course of treatment.
Ranitidine eosinophilic fasciitis
- Ranitidine was used to treat patients with eosinophilic fasciitis with satisfactory results. General medication can be effective within 1 month, and the skin lesions are partially restored after half a year. Usage: Oral ranitidine, 150 mg / time, once each morning, middle and night, warm water for delivery.
Ranitidine non-ulcerative dyspepsia
- Oral ranitidine was used to treat patients with non-ulcerative dyspepsia, and the effect was significant. Among them, the symptom remission rate was 76%. The treatment group was significantly better than the control group. Usage: Oral ranitidine 150 mg / time, 2 times / day, the course of treatment is 6 weeks.
Ranitidine chronic diarrhea
- The disease may cause intestinal wall mast cells to increase and release histamine after stimulation, causing local intestinal hyperemia, edema, and smooth muscle spasm and diarrhea. Ranitidine can play a good therapeutic role by inhibiting histamine release. In most patients, stool can be formed within one week, the number of times is reduced, and the healing effect is obtained. Usage: Oral ranitidine, 150 mg / time, once in the morning, middle and evening, delivered in warm water.
Ranitidine herpes simplex
- Ranitidine is used to treat herpes simplex. Generally, the pain disappears after 3 to 5 times of application. The blisters do not appear in early cases. Those who have blisters dry up and all scab within 2 days. Another person used ranitidine to treat 29 cases of herpes simplex, all of which were cured within 2 to 4 days of treatment. No scar was found after healing. Usage: Take 1 ranitidine capsule (150 mg), dissolve its powder in water, apply it to the affected area after making a solution, and change the dressing once every 1-2 hours.
Ranitidine urticaria
- Some people applied ranitidine to treat urticaria with satisfactory results. After 1 course of treatment, the effective rate was 80%, and the total effective rate was 90%. Methods: Take 5% ranitidine cream and apply it to the shrines, wind ponds, and Xuehai points, each with 50 mg, and cover with a cover of 3.5-6 square centimeters. Change the dressing once every 3 days. 1 course of treatment until the symptoms disappear.
Ranitidine hemophilia
- The use of ranitidine in the treatment of hemophilia can increase the plasma factor or factor concentration, significantly improve clinical symptoms, and stop bleeding within 12 hours after administration. Usage: Oral ranitidine, 150 mg / time, once in the morning and evening. The pediatric dosage decreases by age, and the course of treatment is 15 days. Others continue to use ranitidine for continuous maintenance therapy and have also achieved good results [8] .
Ranitidine expert review
- Ranitidine is effective in treating peptic ulcer. The effect on inhibiting the acid secretion of duodenal ulcer patients at night is 4-9 times stronger than that of imimetidine, but it does not affect gastric mucus and pancreatic enzyme secretion. Without anti-androgenic effect does not affect renal function, the effect on P450 enzymes is less than that of cimetidine [4] .